FREE Shipping on $20+ Orders | Code: SURPRISESHIP ✨

FREE Shipping on ALL Orders | Code: WEEKEND ✨

FREE Shipping on $20+ Orders Code: SURPRISESHIP

A New Weight-Loss Drug May Offer Relief for Aching Knees

man in blue shirt and shorts holding his knee

For millions of people living with painful knee osteoarthritis, simple movements such as walking across a room, climbing stairs, or standing up from a chair can feel like a daily struggle. When excess body weight adds more stress to already damaged joints, the pain can be even more intense. A new set of clinical trials now suggests an experimental weight loss drug called retatrutide may offer meaningful relief for those with knee osteoarthritis who are also overweight or have obesity, combining substantial weight loss with a significant reduction in knee pain.

The phase 3 trials, led by researchers at Northwestern University, enrolled more than 1,000 participants. All were living with painful knee osteoarthritis and carried excess weight. Participants received weekly injections of either retatrutide or a placebo. According to the published findings, those who received the highest dose of retatrutide lost about one quarter of their body weight on average, a level of weight loss that is rarely achieved with lifestyle changes alone. The study team reported that in a pooled analysis, about two thirds of participants on retatrutide experienced at least a 50% reduction in knee pain, compared with 38% of people who received placebo.

A glowing blue digital representation of a human knee joint with molecular structures.

The research team measured pain using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain index, a widely used tool in osteoarthritis research. Participants rated their pain on a scale from 0 to 10 at clinic visits and also recorded daily pain scores in an app. This combination of structured visits and real world daily logging offered a detailed picture of how symptoms changed over time. The magnitude of improvement stood out. For many in the retatrutide group, knee pain became substantially more manageable, and their ability to function in daily life improved along with it.

Retatrutide is an experimental injectable that activates receptors for three natural hormones. That sets it apart from existing GLP 1 medications such as semaglutide or tirzepatide, which currently target one or two receptors and have been associated with weight loss in the range of 10% to 20%. In these trials, retatrutide achieved average weight loss of 20% to 25% in participants, with study investigators noting that some individuals lost as much as 100 pounds or more. The drug is being developed by Eli Lilly, whose scientists co authored the study.

The impact of this degree of weight loss on knee osteoarthritis is significant. Previous research has shown that losing 5% to 10% of body weight through diet and exercise can ease knee osteoarthritis symptoms. Yet the corresponding author, Dr. Thomas Schnitzer of Northwestern University Feinberg School of Medicine, pointed out that losing more than 10% of body weight through lifestyle changes alone is difficult for many people, especially when they are already dealing with substantial knee pain that can make activity challenging. In this context, an option that can help facilitate larger weight reductions could change the landscape of care for painful knee osteoarthritis in people with excess weight.

The trials did not only document improvements in pain and weight. Participants taking retatrutide also experienced reductions in blood pressure, improvements in lipid levels, and lower markers of systemic inflammation. These shifts suggest that the drug’s benefits might extend beyond the joints to broader aspects of cardiometabolic health. The study authors noted that the drugs in this class are believed to have notable anti inflammatory activity, though the precise mechanisms are not fully understood.

Even with these hopeful findings, the researchers emphasized that retatrutide is not intended to replace foundational approaches such as diet, physical activity, and lifestyle modifications. Dr. Schnitzer noted that those strategies remain the first step for people with knee osteoarthritis who are overweight or have obesity. Lifestyle interventions can provide meaningful benefit, are generally more affordable, and do not carry some of the side effects associated with GLP 1 class medications. That point is particularly important for people with knee osteoarthritis, because potential side effects such as loss of muscle mass may matter greatly. Strong muscles help stabilize the knee, support balance, and protect the joint.

At the same time, the reality for many people is that lifestyle changes alone do not deliver the amount of weight loss needed to significantly reduce joint load and chronic pain. When individuals are unable to lose weight through diet and exercise and remain limited by knee pain, the study suggests retatrutide could become an important option if the drug is approved by the U.S. Food and Drug Administration. With approximately 5% of the U.S. population, or around 15 million people, living with painful knee osteoarthritis, the potential reach of such a treatment is large.

Current standard treatments for knee osteoarthritis include corticosteroid injections, which tend to provide only short lived relief, as well as physical therapy, topical agents, non steroidal anti inflammatory drugs like ibuprofen and Voltaren, and sometimes opioids. None of these approaches consistently deliver large and lasting improvements in both pain and underlying joint stress for people whose body weight places high loads on their knees. In that setting, combining a potent weight loss effect with pain reduction is particularly compelling.

Important questions remain. People who already needed total knee replacement were excluded from the trials. As a result, it is not yet clear whether retatrutide can slow the progression of osteoarthritis enough to delay or reduce the need for joint replacement surgery. Dr. Schnitzer highlighted that this is a key unknown, and a central goal for future research. If a medication can both relieve pain and meaningfully slow joint damage, it could reshape how osteoarthritis is managed over the long term.

Another area that requires more study is whether retatrutide could help individuals with painful knee osteoarthritis who are not overweight. Because only people with excess body weight were included in these trials, researchers cannot yet say whether the drug’s potential anti inflammatory effects might benefit those with a normal body weight whose arthritis pain is driven primarily by other factors. Understanding how much of the benefit comes from reduced mechanical load on the joint compared with direct effects on inflammation will be an important focus for future studies.

For now, the findings suggest that for people with both obesity and knee osteoarthritis, targeting significant weight loss with a drug like retatrutide may lead to meaningful reductions in pain, improved function, and better overall health markers. These trials are an early but promising step, and they open the door to more detailed investigations into how osteoarthritis develops and progresses. As research continues, the hope is that treatments can move beyond short term symptom relief toward strategies that truly modify the course of the disease.

Read more at https://news.northwestern.edu/stories/2026/11/experimental-weight-loss-drug-eases-painful-knee-osteoarthritis-in-two-clinical-trials

Back to blog
Customers Also Viewed

Beat the Rush, Shop Now for
the Best Selection

Recommended Just For You
Recently Viewed & Trending Items
DEV MODE ACTIVE. BRAND: gg